兔抗CHRFAM7A多克隆抗體

Background:

The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The family member CHRNA7, which is located on chromosome 15 in a region associated with several neuropsychiatric disorders, is partially duplicated and forms a hybrid with a novel gene from the family with sequence similarity 7 (FAM7A). Alternative splicing has been observed, and two variants exist, for this hybrid gene. The N-terminally truncated products predicted by the largest open reading frames for each variant would lack the majority of the neurotransmitter-gated ion-channel ligand binding domain but retain the transmembrane region that forms the ion channel. Although current evidence supports transcription of this hybrid gene, translation of the nicotinic acetylcholine receptor-like protein-encoding open reading frames has not been confirmed.

Applications:

ELISA, WB, IHC

Name of antibody:

CHRFAM7A

Immunogen:

Synthetic peptide of human CHRFAM7A

Full name:

CHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5-10) and FAM7A (family with sequence similarity 7A, exons A-E) fusion

Synonyms：

D-10, CHRNA7, CHRNA7-DR1

SwissProt:

P36544

ELISA Recommended dilution:

2000-5000

IHC positive control:

Human liver cancer and Human cervical cancer

IHC Recommend dilution:

25-100

WB Predicted band size:

46 kDa

WB Positive control:

Mouse heart tissue

WB Recommended dilution:

500-2000